Neurocrine Biosciences Faces Market Challenges Neurocrine Biosciences stock hit a 52-week low at $110.92, reflecting a 16.26% annual decline. Despite this, the company’s fundamentals remain strong, with revenue growing 24.8% year-over-year. Analysts suggest its current valuation may present a buying opportunity, particularly with management's $500 million share repurchase program underway.3